Other complications associated with artificial fertilization. Complications associated with artificial fertilization
Conditions
Interventions
Intervention 1: Intervention:
Luteal phase support during ART treatment with subcutaneous injections of progesterone (Prolutex): since ovum pick up day, a daily subcutaneous injection of progeste
IBSA Institut, SA Biochimique) will be used and if pregnancy is occurred it continues until 10 weeks of pregnancy. Intervention 2: Control group :
Luteal phase support during ART treatment using a v
Actavis, Barnstaple, UK), If pregnancy is occurred it continues until 10 weeks of pregnancy.
Treatment - Drugs
Intervention:
Luteal phase support during ART treatment with subcutaneous injections of progesterone (Prolutex): since ovum pick up day, a daily subcutaneous injection of progesterone (25 mg) (P
IBSA Institut, SA Biochimique) will be used and if pregnancy is occurred it continues until 10 weeks of pregnancy.
Control group :
Luteal phase support during ART treatment using a vaginal suppository (Cyclogest) : Since ovum pick up day, one vaginal suppository every 12 hours will be used (Cyclogest ®
Sponsors
Royan Institute
Shafayab Gostar company
Eligibility
Sex/Gender
Female
Age
19 Years to 39 Years
Inclusion criteria
Inclusion criteria: Inclusion Criteria: Female age 19–39 years ; An written consent to participate in the study ;Body mass index (BMI ) <30 kg/m2 Exclusion Criteria: Severe male infertility (TESE, PESA) ; The uterine cause of infertility (uterine surgery history, cervical insufficiency, submucosal myoma or intramural fibroids = 5 cm and multiple uterine polyps) ; Patients with poor ovarian response or patients with reduced ovarian reserve (FSH = 15 IU/ml, AMH = 1 ng/ml) ; Tubal factor was diagnosed as hydrosalpinx ; Moderate and severe endometriosis (stage3and 4) ; Cases of repeated implantation failure (RIF) and spontaneous abortions.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical pregnancy rate. Timepoint: Evidence of pregnancy by clinical (fetal heartbeat) or ultrasound parameters (ultrasound visualization of a gestational sac, embryonic pole with heartbeat)after 7-6 weeks after embryos transfer. Method of measurement: Vaginal sonography.;Pain during drug use. Timepoint: The patient records pain during drug using based on visual scale from 0 to 10. Method of measurement: Visual analog scale.;Comfort and satisfaction of drug. Timepoint: The patient records comfort and satisfaction during drug using based on visual scale from 0 to 10. Method of measurement: Visual analog scale. | — |
Secondary
| Measure | Time frame |
|---|---|
| Early Miscarriage rate. Timepoint: spontaneous loss of a pregnancy before 12 weeks. Method of measurement: Vaginal sonography. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Ashraf Moini
Royan Institute
Outcome results
None listed